Cargando…

PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension

High blood pressure and its associated cardiovascular diseases have been major risks for public health. Multiple metabolic risk factors can cause the vascular dysfunction and vascular lesion, and the hypertension due to metabolic disturbances was defined as metabolic hypertension. The members of a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yanli, Li, Qiang, Jia, Mengxiao, Yan, Zhencheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470447/
https://www.ncbi.nlm.nih.gov/pubmed/31073415
http://dx.doi.org/10.1155/2019/7809216
_version_ 1783411799112024064
author Jiang, Yanli
Li, Qiang
Jia, Mengxiao
Yan, Zhencheng
author_facet Jiang, Yanli
Li, Qiang
Jia, Mengxiao
Yan, Zhencheng
author_sort Jiang, Yanli
collection PubMed
description High blood pressure and its associated cardiovascular diseases have been major risks for public health. Multiple metabolic risk factors can cause the vascular dysfunction and vascular lesion, and the hypertension due to metabolic disturbances was defined as metabolic hypertension. The members of a subfamily of the nuclear receptors, peroxisome proliferator-activated receptors (PPARs), were found to be key regulators of metabolism and vascular function. We provide up-to-date knowledge on the role of subtype PPARδ in the regulation of metabolism and vascular function and the effect of its intervention on the metabolic hypertension management. We hope to give some insights into the development of more effective treatments of metabolic hypertension and its main complications.
format Online
Article
Text
id pubmed-6470447
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64704472019-05-09 PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension Jiang, Yanli Li, Qiang Jia, Mengxiao Yan, Zhencheng Int J Hypertens Review Article High blood pressure and its associated cardiovascular diseases have been major risks for public health. Multiple metabolic risk factors can cause the vascular dysfunction and vascular lesion, and the hypertension due to metabolic disturbances was defined as metabolic hypertension. The members of a subfamily of the nuclear receptors, peroxisome proliferator-activated receptors (PPARs), were found to be key regulators of metabolism and vascular function. We provide up-to-date knowledge on the role of subtype PPARδ in the regulation of metabolism and vascular function and the effect of its intervention on the metabolic hypertension management. We hope to give some insights into the development of more effective treatments of metabolic hypertension and its main complications. Hindawi 2019-04-03 /pmc/articles/PMC6470447/ /pubmed/31073415 http://dx.doi.org/10.1155/2019/7809216 Text en Copyright © 2019 Yanli Jiang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Jiang, Yanli
Li, Qiang
Jia, Mengxiao
Yan, Zhencheng
PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
title PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
title_full PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
title_fullStr PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
title_full_unstemmed PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
title_short PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
title_sort pparδ: a potential therapeutic target for the treatment of metabolic hypertension
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470447/
https://www.ncbi.nlm.nih.gov/pubmed/31073415
http://dx.doi.org/10.1155/2019/7809216
work_keys_str_mv AT jiangyanli ppardapotentialtherapeutictargetforthetreatmentofmetabolichypertension
AT liqiang ppardapotentialtherapeutictargetforthetreatmentofmetabolichypertension
AT jiamengxiao ppardapotentialtherapeutictargetforthetreatmentofmetabolichypertension
AT yanzhencheng ppardapotentialtherapeutictargetforthetreatmentofmetabolichypertension